Security key
00166B105
ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (ALXO)
CUSIP: 00166B105
Q2 2024 13F Holders as of 30 Jun 2024
- Security type / class
- Equity / Common Stock, par value $0.001 per share
- Total 13F shares
- 48,509,608
- Total 13F value
- $292,389,850
- Share change
- +2,790,309
- Put/Call ratio
- 27%
- SEC-reported price per share
- $6.03
- Number of holders
- 107
- Value change
- -$2,826,841
- Number of buys
- 66
- Number of sells
- 50
- Shares outstanding
- 133,751,136
Holder snapshot
7 signals
Open additional details 1 more signal available
Security identity
Names, identifiers, and filing context for this profile.
1 source field
Report period
Q2 2024
Institutions
107
Top holders
10
ALXO full security history
Ownership snapshot
Full 13F holder table
Newer quarter: Q3 2024
Previous quarter: Q1 2024
ALX ONCOLOGY HOLDINGS INC SEC filings
ALX ONCOLOGY HOLDINGS INC company facts
Broader feeds
Reporting periods
Holder history for CUSIP 00166B105
Recent filing periods:
Ownership snapshot
Top reported holders of ALXO - ALX ONCOLOGY HOLDINGS INC - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
venBio Partners LLC
Disclosed value leader
venBio Partners LLC
Comparable rows
15/15
Latest evidence
31 Mar 2024
13F
Lead comparable stake: 7.3%
Showing 1-6 of 15 holder rows.
Quick read
venBio Partners LLC leads the comparable SEC ownership view at 7.3%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens venBio Partners LLC's linked filing trail.
Comparable ownership
Top 5
venBio Partners LLC
7.3%
FMR LLC
5.6%
Redmile Group, LLC
3.2%
Vivo Capital, LLC
3.2%
Cormorant Asset Management, LP
2.3%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| venBio Partners LLC |
13F
Company
|
7.3%
|
$108,154,164
9,699,925 shares
|
— | 31 Mar 2024 |
| FMR LLC |
13F
Company
|
5.6%
|
$83,879,354
7,522,812 shares
|
— | 31 Mar 2024 |
| Redmile Group, LLC |
13F
Company
|
3.2%
|
$48,240,575
4,326,509 shares
|
— | 31 Mar 2024 |
| Vivo Capital, LLC |
13F
Company
|
3.2%
|
$47,053,535
4,220,048 shares
|
— | 31 Mar 2024 |
| Cormorant Asset Management, LP |
13F
Company
|
2.3%
|
$35,034,181
3,142,079 shares
|
— | 31 Mar 2024 |
| ORBIMED ADVISORS LLC |
13F
Company
|
2%
|
$30,305,366
2,717,970 shares
|
— | 31 Mar 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q2 2024
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
107
Shares
48,509,608
Rows available
107
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
105
Q2 2024 holders
107
Holder diff
2
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 value | Q2 2024 value | Value change | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend